Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

APM
Aptorum Group Limited Class A
stock NASDAQ

At Close
May 8, 2025
0.8608USD0.000%(0.0000)10,345
0.00Bid   0.00Ask   0.0000Spread
Pre-market
May 9, 2025 8:00:30 AM EDT
0.8600USD-0.093%(-0.0008)200
After-hours
May 8, 2025 4:25:30 PM EDT
0.8308USD0.000%(+0.8308)391
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
05:01AM EST  41 Biggest Movers From Yesterday   Benzinga
Jan 20, 2022
05:06AM EST  Aptorum International Limited Received FDA Orphan Drug Designation Wednesday for Rilpivirine for Treatment of Neuroblastoma   Benzinga
Jan 18, 2022
08:09AM EST  Aptorum Group Granted The First Patent For Its SACT-1 Repurposed Drug For Treatment of Various Cancer Including But Not Limited To Neuroblastoma   Benzinga
Jan 10, 2022
08:24AM EST  Aptorum Group Highlights Launch Of Its Oncology, Autoimmune Discovery, Development Platform Targeting Unmet Mutations, Novel Biomarkers   Benzinga
08:21AM EST  Aptorum Group Offers Update On Clinical Validation Of Its Infectious Disease Liquid Biopsy Technology   Benzinga
08:19AM EST  Aptorum Group Reports Completion Of Phase 1 Trials For ALS-4, SACT-1 For Infections Caused By Staphylococcus Aureus, Neuroblastoma   Benzinga
Nov 9, 2021
02:32PM EST  Aptorum Shares Volatile Following Circulation Of US Patent & Trademark Office Abstract For Co.'s 'Composition including rilpivirine and method for treating tumors or cancer'   Benzinga
Nov 4, 2021
01:55PM EDT  Andean Precious Metals to Webcast Live at VirtualInvestorConferences.com on   PR Newswire
Sep 15, 2021
08:11AM EDT  Aptorum Group H1 EPS $(0.47) Down From $(0.21) YoY, Sales $637.78K Up From $327.27K YoY   Benzinga
08:01AM EDT  Aptorum Group Limited Has Received IND Clearance From FDA To Initiate Clinical Trials For Repurposed Small Molecule Drug SACT-1 For The Treatment Of Neuroblastoma   Benzinga
Jul 12, 2021
08:59AM EDT  Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate   Benzinga
08:42AM EDT  Aptorum's Shares Jump After ALS-4 Targeting Staphylococcus Aureus Shows Encouraging Action In Early-Stage Study   Benzinga
08:07AM EDT  Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus   Benzinga
May 26, 2021
08:19AM EDT  Aptorum Group Reports Founder, CEO Purchased ~1.388M Shares Of Co.'s Common Stock   Benzinga
May 24, 2021
12:15PM EDT  Mid-Day Market Update: Crude Oil Rises 2.5%; NGM Biopharmaceuticals Shares Plunge   Benzinga
11:58AM EDT  Aptorum's Shares Jump After ALS-4 Targeting Staphylococcus Aureus Shows Encouraging Action In Early-Stage Study   Benzinga
08:02AM EDT  Aptorum Group Highlights Interim Phase I Clinical Trial Progress For ALS-4 And Pre-IND Progress For SACT-1   Benzinga
May 14, 2021
06:48AM EDT  Schedule For Benzinga's Global Small Cap Conference Friday, May 14, 2021   Benzinga
May 6, 2021
07:39AM EDT  Aptorum Says Group Enters Into Agreement With Exeltis To Develop Aptorum's Novel Preclinical Candidate Targeting Woman's Gynecological Conditions   Benzinga
Apr 22, 2021
09:04AM EDT  Aptorum Shares Are Trading Higher On Immunomodulators Agreement For Autoimmune, Oncology Indications   Benzinga
07:20AM EDT  Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases   Benzinga
Apr 5, 2021
11:30AM EDT  Andean Virtually Opens The Market   PR Newswire
Mar 31, 2021
09:54AM EDT  Aptorum ALS-4 Study Starts Dosing In Healthy Volunteers   Benzinga
07:10AM EDT  Aptorum Group Announces Dosing First Human Subject In A Phase I Clinical Trial Of ALS-4, A First-In-Class Small Molecule Drug Designed To Treat Infections Caused By Staphylococcus Aureus Including Methicillin-resistant Staphylococcus Aureus   Benzinga
Mar 26, 2021
04:32PM EDT  IIROC Trading Resumption - APM   PR Newswire
Jan 20, 2021
10:35AM EST  Shares of Aptorum Group Ltd. (APM) jumped over 30% on Wednesday morning after the company received clearance from Canada health regulator to commence a phase 1 trial of ALS-4 for infections caused by staphylococcus aureus.   RTTNews
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
06:02AM EST  Aptorum Group Receives Health Canada Clearance To Initiate Phase 1 Clinical Trial For ALS-4, A Small Molecule Drug For Infections Caused By Staphylococcus Aureus including MRSA   Benzinga
Dec 21, 2020
06:05AM EST  Aptorum Group Announces Submission of Clinical Trial Application for ALS-4, an Orally Administered Small Molecule Drug for the Treatment of Infections caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)   Benzinga
Oct 9, 2020
10:06AM EDT  Mometum Makes A Comeback As The Weather Cools Down   Benzinga
Sep 30, 2020
03:55PM EDT  Mid-Afternoon Market Update: Dow Jumps 350 Points; Iterum Therapeutics Shares Spike Higher   Benzinga
12:45PM EDT  Mid-Day Market Update: Crude Oil Rises Over 1%; Aptorum Group Shares Plummet   Benzinga
10:11AM EDT  Mid-Morning Market Update: Markets Open Higher; Micron Issues Weak Earnings Forecast   Benzinga
Sep 29, 2020
03:06PM EDT  Mid-Afternoon Market Update: Gold Rises 1%; Myovant Sciences Shares Plunge   Benzinga
12:01PM EDT  Mid-Day Market Update: Dow Tumbles Over 200 Points; Aptorum Group Shares Jump   Benzinga
06:01AM EDT  Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Genome   Benzinga
Sep 2, 2020
08:19AM EDT  Aptorum Group Announces Video Update Discussing Positive Data On SACT-1 Against Neuroblastoma, Other Potential Tumor Types   Benzinga
Sep 1, 2020
07:22AM EDT  Aptorum Group Earlier Announced Data Sets On ALS-4 Against MRSA   Benzinga
07:20AM EDT  Aptorum Group Earlier Announced Data From In Vivo Studies Of SACT-1 Against Neuroblastoma And Other Potential Tumor Types   Benzinga
Jul 17, 2020
06:22AM EDT  Aptroum Group Reports Receives Approval For Listing On Euronext Paris Exchange   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC